These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 37734395)

  • 1. Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide study.
    Malik ME; Butt JH; Strange JE; Falkentoft AC; Jensen J; Andersson C; Zahir D; Fosbøl E; Petrie MC; Sattar N; McMurray JJV; Køber L; Schou M
    Lancet Healthy Longev; 2023 Oct; 4(10):e552-e560. PubMed ID: 37734395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in people with type 2 diabetes in Taiwan: a retrospective, nationwide, longitudinal study.
    Hsiao FY; Tan EC; Meng LC; Lin YC; Chen HM; Guan ST; Tarng DC; Wang CY; Chen LK
    Lancet Healthy Longev; 2024 Sep; 5(9):100621. PubMed ID: 39284334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age disparities in glucose-lowering treatment for Danish people with type 2 diabetes: a cross-sectional study between 2019 and 2020.
    Johansson KS; Bülow C; Jimenez-Solem E; Petersen TS; Christensen MB
    Lancet Healthy Longev; 2023 Dec; 4(12):e685-e692. PubMed ID: 38042161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A Scandinavian cohort study.
    Ueda P; Wintzell V; Dahlqwist E; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Melbye M; Hviid A; Svanström H; Pasternak B
    Diabetes Obes Metab; 2022 Mar; 24(3):473-485. PubMed ID: 34738703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes.
    Lim CE; Pasternak B; Eliasson B; Danaei G; Ueda P
    Eur J Prev Cardiol; 2023 Jun; 30(8):634-643. PubMed ID: 36582120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
    Dong YH; Chang CH; Lin JW; Yang WS; Wu LC; Toh S
    Diabetes Obes Metab; 2022 Aug; 24(8):1623-1637. PubMed ID: 35491533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis.
    Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC)
    Lancet Diabetes Endocrinol; 2021 Dec; 9(12):825-836. PubMed ID: 34656210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
    Patorno E; Htoo PT; Glynn RJ; Schneeweiss S; Wexler DJ; Pawar A; Bessette LG; Chin K; Everett BM; Kim SC
    Ann Intern Med; 2021 Nov; 174(11):1528-1541. PubMed ID: 34570599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.
    Apperloo EM; Neuen BL; Fletcher RA; Jongs N; Anker SD; Bhatt DL; Butler J; Cherney DZI; Herrington WG; Inzucchi SE; Jardine MJ; Liu CC; Mahaffey KW; McGuire DK; McMurray JJV; Neal B; Packer M; Perkovic V; Sabatine MS; Solomon SD; Staplin N; Szarek M; Vaduganathan M; Wanner C; Wheeler DC; Wiviott SD; Zannad F; Heerspink HJL
    Lancet Diabetes Endocrinol; 2024 Aug; 12(8):545-557. PubMed ID: 38991584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: A nationwide cohort study.
    Al-Mashhadi ZK; Viggers R; Starup-Linde J; Vestergaard P; Gregersen S
    Front Endocrinol (Lausanne); 2022; 13():861422. PubMed ID: 36060970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes.
    Neves JS; Borges-Canha M; Vasques-Nóvoa F; Green JB; Leiter LA; Granger CB; Carvalho D; Leite-Moreira A; Hernandez AF; Del Prato S; McMurray JJV; Ferreira JP
    J Am Coll Cardiol; 2023 Aug; 82(6):517-525. PubMed ID: 37532422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.
    Hussein H; Zaccardi F; Khunti K; Seidu S; Davies MJ; Gray LJ
    Diabet Med; 2019 Apr; 36(4):444-452. PubMed ID: 30653708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: A real-world study in two Italian cohorts.
    Baviera M; Genovese S; Lepore V; Colacioppo P; Robusto F; Tettamanti M; D'Ettorre A; Avanzini F; Fortino I; Nicolucci A; Roncaglioni MC; Giorgino F
    Diabetes Obes Metab; 2021 Jul; 23(7):1484-1495. PubMed ID: 33606897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.
    Brown E; Heerspink HJL; Cuthbertson DJ; Wilding JPH
    Lancet; 2021 Jul; 398(10296):262-276. PubMed ID: 34216571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of DPP4 Inhibitors and GLP-1 Receptor Agonists and Risk of Intestinal Obstruction: Scandinavian Cohort Study.
    Ueda P; Wintzell V; Melbye M; Eliasson B; Söderling J; Gudbjörnsdottir S; Hveem K; Jonasson C; Svanström H; Hviid A; Pasternak B
    Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1226-1237.e14. PubMed ID: 37716613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Sodium-Glucose Cotransporter 2 Inhibitors vs Glucagonlike Peptide-1 Receptor Agonists and Incidence of Dry Eye Disease in Patients With Type 2 Diabetes in Taiwan.
    Su YC; Hung JH; Chang KC; Sun CC; Huang YH; Lee CN; Hung MJ; Lai CC; Shao SC; Lai EC
    JAMA Netw Open; 2022 Sep; 5(9):e2232584. PubMed ID: 36136333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease.
    Luo J; Feldman R; Callaway Kim K; Rothenberger S; Korytkowski M; Hernandez I; Gellad WF
    JAMA Netw Open; 2023 Jun; 6(6):e2317886. PubMed ID: 37307000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.
    Yamada T; Wakabayashi M; Bhalla A; Chopra N; Miyashita H; Mikami T; Ueyama H; Fujisaki T; Saigusa Y; Yamaji T; Azushima K; Urate S; Suzuki T; Abe E; Wakui H; Tamura K
    Cardiovasc Diabetol; 2021 Jan; 20(1):14. PubMed ID: 33413348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.